Main Category: Bones / Orthopedics
Also Included In: Menopause;��Clinical Trials / Drug Trials;��Women's Health / Gynecology
Article Date: 28 Apr 2011 - 6:00 PDT
email to a friend � 
printer friendly � 
opinions � 
Current Article Ratings:
| Patient / Public: |  | |
| Healthcare Prof: | |
Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women. Unigene is developing its oral PTH in collaboration with GlaxoSmithKline (GSK) as part of an exclusive worldwide licensing agreement. According to the agreement with GSK, Unigene will receive a $4M milestone payment for completion of Phase 2 patient enrollment.
Ashleigh Palmer, President and Chief Executive Officer of Unigene Laboratories, Inc., said, "The completion of enrollment in this Phase 2 study with our proprietary oral formulation of the recombinantly produced PTH analog is a significant development milestone for Unigene. We are thrilled to have achieved this goal and remain focused on advancing this program that we believe has the potential to address an important medical need." Palmer continued, "I am extremely impressed with the Unigene team's execution of this study in just four months since the signing of our collaboration with GSK, and believe this not only showcases our clinical trial expertise, but represents an important competitive advantage."
Phase 2 Study Design
This multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study will include an open label comparator arm of the Forsteo� injectable formulation. The primary endpoint will be an increase in bone mineral density (BMD) at the lumbar spine in subjects at 24 weeks in 93 postmenopausal osteoporotic women following once daily treatment with the orally delivered PTH analog compared to baseline. Secondary endpoints will evaluate biochemical markers of bone formation and resorption, as well as the safety, tolerability and pharmacokinetics of the oral formulation.
The Company expects to report top-line results before year end.
About Osteoporosis
Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or symptoms. The disease has a significant impact on patients' quality of life and it is estimated that one in three women and one in five men over the age of 50 will develop osteoporosis during their lifetimes.
The prevalence of osteoporosis is growing as the number of post-menopausal women rises, along with the general increase in life expectancy. Osteoporosis affects an estimated 75 million people in Europe, the US and Japan. In women over 45, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, heart attack and breast cancer. There is currently no cure for osteoporosis, but available treatments can strengthen bones and help reduce the risk of fractures.
About Unigene-GSK Agreement
On December 10, 2010, Unigene entered into an amended and restated exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women. Under the terms of the amended and restated agreement, Unigene is responsible for the manufacture of the PTH and the conduct of the Phase 2 study. The Company received an upfront payment of $4M to cover costs associated with the Phase 2 study, and will also receive an additional $4M payment upon completion of Phase 2 patient enrollment, as well as further payments of up to $142M based on the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered double-digit royalties in the low-to-mid teens on global sales. Once the Phase 2 study has been completed and based on a review of the data, GSK may elect to assume responsibility for all future development and commercialization of the product.
Source:
Unigene Laboratories, Inc.
| Please rate this article: (Hover over the stars then click to rate) | Patient / Public: | or | Health Professional: |
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd � 2004-2011 All rights reserved.
Source: http://www.medicalnewstoday.com/articles/223627.php
health care for women womens-health.co.uk black women health male health issues health advice for women
No comments:
Post a Comment